257 related articles for article (PubMed ID: 26029997)
1. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.
Sachweh MC; Stafford WC; Drummond CJ; McCarthy AR; Higgins M; Campbell J; Brodin B; Arnér ES; Laín S
Oncotarget; 2015 Jun; 6(18):16488-506. PubMed ID: 26029997
[TBL] [Abstract][Full Text] [Related]
2. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.
Hedström E; Eriksson S; Zawacka-Pankau J; Arnér ES; Selivanova G
Cell Cycle; 2009 Nov; 8(21):3584-91. PubMed ID: 19838062
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
[TBL] [Abstract][Full Text] [Related]
4. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose.
Du Y; Zhang H; Lu J; Holmgren A
J Biol Chem; 2012 Nov; 287(45):38210-9. PubMed ID: 22977247
[TBL] [Abstract][Full Text] [Related]
5. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.
Schuh E; Pflüger C; Citta A; Folda A; Rigobello MP; Bindoli A; Casini A; Mohr F
J Med Chem; 2012 Jun; 55(11):5518-28. PubMed ID: 22621714
[TBL] [Abstract][Full Text] [Related]
6. Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer.
Oh BM; Lee SJ; Cho HJ; Park YS; Kim JT; Yoon SR; Lee SC; Lim JS; Kim BY; Choe YK; Lee HG
Cell Death Dis; 2017 Mar; 8(3):e2682. PubMed ID: 28300829
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.
Kiebala M; Skalska J; Casulo C; Brookes PS; Peterson DR; Hilchey SP; Dai Y; Grant S; Maggirwar SB; Bernstein SH
Exp Hematol; 2015 Feb; 43(2):89-99. PubMed ID: 25448488
[TBL] [Abstract][Full Text] [Related]
8. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion.
You BR; Park WH
Oncol Rep; 2016 Jan; 35(1):546-51. PubMed ID: 26530353
[TBL] [Abstract][Full Text] [Related]
9. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
[TBL] [Abstract][Full Text] [Related]
10. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.
Fiskus W; Saba N; Shen M; Ghias M; Liu J; Gupta SD; Chauhan L; Rao R; Gunewardena S; Schorno K; Austin CP; Maddocks K; Byrd J; Melnick A; Huang P; Wiestner A; Bhalla KN
Cancer Res; 2014 May; 74(9):2520-32. PubMed ID: 24599128
[TBL] [Abstract][Full Text] [Related]
11. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Bhatia M; Tonissen KF
Oncotarget; 2015 Jun; 6(17):15410-24. PubMed ID: 25945832
[TBL] [Abstract][Full Text] [Related]
13. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
14. Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells.
Tanaka G; Inoue K; Shimizu T; Akimoto K; Kubota K
Cancer Med; 2016 Sep; 5(9):2544-57. PubMed ID: 27485632
[TBL] [Abstract][Full Text] [Related]
15. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.
Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H
Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352
[TBL] [Abstract][Full Text] [Related]
16. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
17. Daucosterol disturbs redox homeostasis and elicits oxidative-stress mediated apoptosis in A549 cells via targeting thioredoxin reductase by a p53 dependent mechanism.
Rajavel T; Banu Priya G; Suryanarayanan V; Singh SK; Pandima Devi K
Eur J Pharmacol; 2019 Jul; 855():112-123. PubMed ID: 31059712
[TBL] [Abstract][Full Text] [Related]
18. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
19. The thioredoxin system in breast cancer cell invasion and migration.
Bhatia M; McGrath KL; Di Trapani G; Charoentong P; Shah F; King MM; Clarke FM; Tonissen KF
Redox Biol; 2016 Aug; 8():68-78. PubMed ID: 26760912
[TBL] [Abstract][Full Text] [Related]
20. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
